PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Pigorsch, S.U.* ; Kampfer, S.* ; Oechsner, M.* ; Mayinger, M.C.* ; Mozes, P.* ; Devecka, M.* ; Kessel, K.K.* ; Combs, S.E. ; Wilkens, J.J.*

Report on planning comparison of VMAT, IMRT and helical tomotherapy for the ESCALOX-trial pre-study.

Radiat. Oncol. 15:253 (2020)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques. Methods: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conformity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation index (COIN) for parotids. Results: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral parotids favor HT. Conclusion: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT. Trial registration ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
2.817
1.167
6
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Combined Chemoradiation Therapy ; Dose Escalation ; Head And Neck Cancer ; Helical Tomotherapy ; Imrt ; Rt Planning Comparison ; Sib ; Vmat; Simultaneous Integrated Boost; Modulated Radiation-therapy; Target Volume Delineation; Squamous-cell Carcinoma; Locally Advanced Head; Neck-cancer; Dose-escalation; Arc Therapy; Oropharyngeal Cancer; Radiotherapy
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 1748-717X
e-ISSN 1748-717X
Zeitschrift Radiation Oncology
Quellenangaben Band: 15, Heft: 1, Seiten: , Artikelnummer: 253 Supplement: ,
Verlag BioMed Central
Verlagsort Campus, 4 Crinan St, London N1 9xw, England
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Radiation Sciences
PSP-Element(e) G-501300-001
Förderungen Deutsche Forschungsgemeinschaft (DFG)
DOI 10.1186/s13014-020-01693-2
WOS ID WOS:000589721100002
Scopus ID 85094926477
PubMed ID 33138837
Erfassungsdatum 2020-12-08
[➜Korrektur melden]